B細胞成熟抗原（BCMA）標的療法の世界市場レポート 2025年

B細胞成熟抗原（BCMA）標的療法市場規模は、今後数年で飛躍的な成長が見込まれます。2029年にはCAGR24.6%で366億6,000万米ドルに成長します。予測期間中に予想される成長の原動力となるのは、がん研究への継続的な注力、特定の分子マーカーを標的とする方向へのシフト、がん罹患率の上昇、バイオテクノロジーへの投資の急増、細胞・遺伝子治療の利用拡大です。予測期間における主な動向としては、CRISPR技術などの発展、遺伝子編集技術の進歩、次世代CAR-T細胞療法の開発、標的抗体薬物複合体の進歩、既製治療の創出などが挙げられます。

多発性骨髄腫の有病率の増加は、B細胞成熟抗原（BCMA）標的療法市場の拡大を牽引すると予想されます。多発性骨髄腫は、主に形質細胞（抗体産生を担う免疫系の重要な構成要素）に影響を与えるがんであり、世界の高齢化、診断ツールの強化、ヘルスケアへのアクセスレベルのばらつきなどの要因により、より一般的になりつつあります。BCMA標的治療は、BCMAを発現する悪性形質細胞の排除に焦点を当て、より正確で効果的な治療法を提供するため、この疾患の治療には不可欠です。例えば、米国がん協会は、2024年に米国で新たに多発性骨髄腫が約35,780例（男性19,520例、女性16,260例）発生すると予測しています。予想される死亡者数は約1万2,540人で、男性が7,020人、女性が5,520人です。その結果、このがんの罹患率の増加がBCMA標的治療薬市場の成長に拍車をかけています。

B細胞成熟抗原（BCMA）標的療法市場の主要企業は、がん細胞を標的とする効果と精度を向上させるため、CAR-T細胞療法などの最先端治療の開発に注力しています。CAR-T細胞療法は、患者のT細胞をキメラ抗原受容体（CAR）を発現するように変化させ、がん細胞を特異的に攻撃・排除できるようにする免疫療法です。例えば、2024年4月、米国の製薬会社ジョンソン・エンド・ジョンソンが、CARVYKTIの承認を米国食品医薬品局（FDA）から取得しました。CARVYKTI（ciltacabtagene autoleucel）はBCMAを標的とした遺伝子組換え自己T細胞療法で、レナリドミドに抵抗性を示す再発または難治性の多発性骨髄腫の成人患者を治療するために開発されました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界B細胞成熟抗原（BCMA）標的療法PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のB細胞成熟抗原（BCMA）標的療法市場：成長率分析
• 世界のB細胞成熟抗原（BCMA）標的療法市場の実績：規模と成長, 2019-2024
• 世界のB細胞成熟抗原（BCMA）標的療法市場の予測：規模と成長, 2024-2029, 2034F
• 世界B細胞成熟抗原（BCMA）標的療法総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のB細胞成熟抗原（BCMA）標的療法市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗体薬物複合体
• キメラ抗原受容体T（CAR-T）細胞療法
• 二重特異性抗体
• 世界のB細胞成熟抗原（BCMA）標的療法市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性リンパ性白血病
• 多発性骨髄腫
• 世界のB細胞成熟抗原（BCMA）標的療法市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 在宅ケア設定
• 世界のB細胞成熟抗原（BCMA）標的療法市場抗体薬物複合体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• BCMA標的ADC（抗体薬物複合体）
• リンカーペイロード技術ベースのBCMA ADC
• 世界のB細胞成熟抗原（BCMA）標的療法市場キメラ抗原受容体T（CAR-T）細胞療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• BCMA CAR-T細胞（自己）
• 同種BCMA CAR-T細胞
• 世界のB細胞成熟抗原（BCMA）標的療法市場二重特異性抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• BCMA x CD3二重特異性抗体
• BCMA x CD28二重特異性抗体

第7章 地域別・国別分析

• 世界のB細胞成熟抗原（BCMA）標的療法市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のB細胞成熟抗原（BCMA）標的療法市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• B細胞成熟抗原（BCMA）標的療法市場：競合情勢
• B細胞成熟抗原（BCMA）標的療法市場：企業プロファイル
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Novartis Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline（GSK）Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Regeneron Pharmaceuticals
• Beigene
• Arcellx Inc
• Poseida Therapeutics
• Legend Biotech Corporation
• Cartesian Therapeutics
• Juno Therapeutics
• Sutro Biopharma Inc
• CARsgen Therapeutics
• Precision BioSciences
• Eureka Therapeutics Inc
• Cellectis
• Teneobio Inc.
• Janssen Pharmaceuticals Companies
• Allogene Therapeutics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• B細胞成熟抗原（BCMA）標的療法市場2029：新たな機会を提供する国
• B細胞成熟抗原（BCMA）標的療法市場2029：新たな機会を提供するセグメント
• B細胞成熟抗原（BCMA）標的療法市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

B-cell maturation antigen (BCMA) targeted therapies are a class of treatments designed to specifically target BCMA, a protein found on the surface of mature B-cells and plasma cells. BCMA, a member of the tumor necrosis factor (TNF) receptor superfamily, plays an essential role in B-cell development, survival, and differentiation into plasma cells. These therapies represent a significant advancement in treating multiple myeloma, providing effective options for patients with relapsed or refractory disease.

The main types of products in BCMA-targeted therapies include antibody-drug conjugates (ADCs), chimeric antigen receptor T (CAR-T) cell therapy, and bispecific antibodies. ADCs are targeted treatments that attach a cancer-specific antibody to a cytotoxic drug, allowing for the precise destruction of cancer cells while minimizing damage to healthy tissue. The primary indications for these therapies include acute lymphoblastic leukemia and multiple myeloma. These treatments are used by various end users, such as hospitals, specialty clinics, and home care settings.

The B-cell maturation antigen (BCMA) targeted therapies market research report is one of a series of new reports from The Business Research Company that provides B-cell maturation antigen (BCMA) targeted therapies market statistics, including the B-cell maturation antigen (BCMA) targeted therapies industry global market size, regional shares, competitors with the B-cell maturation antigen (BCMA) targeted therapies market share, detailed B-cell maturation antigen (BCMA) targeted therapies market segments, market trends, and opportunities, and any further data you may need to thrive in the B-cell maturation antigen (BCMA) targeted therapies industry. This B-cell maturation antigen (BCMA) targeted therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The B-cell maturation antigen (BCMA) targeted therapies market size has grown exponentially in recent years. It will grow from $12.17 billion in 2024 to $15.21 billion in 2025 at a compound annual growth rate (CAGR) of 25.0%. The growth during the historical period can be attributed to an increasing focus on hematologic malignancies, rising investments in oncology research, a growing demand for personalized medicine, higher adoption of CAR-T cell therapies, and rising healthcare expenditure.

The B-cell maturation antigen (BCMA) targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $36.66 billion in 2029 at a compound annual growth rate (CAGR) of 24.6%. The expected growth in the forecast period is driven by a continued focus on cancer research, a shift toward targeting specific molecular markers, the rising incidence of cancers, a surge in biotech investments, and the expanding use of cell and gene therapies. Key trends in the forecast period include innovations such as CRISPR technology, advancements in gene-editing technologies, the development of next-generation CAR-T cell therapies, progress in targeted antibody-drug conjugates, and the creation of off-the-shelf treatments.

The growing prevalence of multiple myeloma is anticipated to drive the expansion of the B-cell maturation antigen (BCMA) targeted therapies market. Multiple myeloma, a cancer that mainly impacts plasma cells-vital components of the immune system responsible for antibody production-is becoming more common due to factors such as an aging global population, enhanced diagnostic tools, and varying levels of healthcare access. BCMA-targeted therapies are essential for treating this condition, as they focus on eliminating malignant plasma cells expressing BCMA, offering a more precise and effective treatment option. For example, the American Cancer Society projected that in 2024, the United States would see approximately 35,780 new multiple myeloma cases, including 19,520 in men and 16,260 in women. The expected death toll is around 12,540, with 7,020 male deaths and 5,520 female deaths. As a result, the increasing incidence of this cancer is fueling growth in the BCMA-targeted therapies market.

Leading companies in the B-cell maturation antigen (BCMA) targeted therapies market are focusing on developing cutting-edge treatments such as CAR-T cell therapy to improve the effectiveness and accuracy of targeting cancer cells. CAR-T cell therapy is an immunotherapy that involves altering a patient's T cells to express chimeric antigen receptors (CARs), enabling them to specifically attack and eliminate cancer cells. For example, in April 2024, Johnson & Johnson, a U.S.-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is a BCMA-targeted, genetically modified autologous T-cell therapy designed to treat adults with relapsed or refractory multiple myeloma who have undergone at least one previous line of treatment and are resistant to lenalidomide.

In February 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for around $1.2 billion. This acquisition is aimed at strengthening AstraZeneca's cell therapy portfolio by incorporating Gracell's FasTCAR-enabled GC012F therapy, which targets cancer and autoimmune diseases, addressing critical unmet medical needs. Gracell Biotechnologies, based in China, specializes in developing BCMA therapies for multiple myeloma and B-cell malignancies.

Major players in the b-cell maturation antigen (bcma) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline (GSK), Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, Beigene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Juno Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Teneobio Inc., Janssen Pharmaceuticals Companies, Allogene Therapeutics, Affimed, Bluebird Bio Inc.

North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2024. The regions covered in B-cell maturation antigen (BCMA) targeted therapies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the B-cell maturation antigen (BCMA) targeted therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The B-cell maturation antigen (BCMA) targeted therapies market consists of revenues earned by entities by providing services such as research and development services, clinical trials management, manufacturing and production services, regulatory consulting and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The B-cell maturation antigen (BCMA) targeted therapies market also includes sales of antibody-drug conjugates (ADCs), BCMA-targeted immunotherapies, and gene therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

B-Cell Maturation Antigen (BCMA) Targeted Therapies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on b-cell maturation antigen (bcma) targeted therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for b-cell maturation antigen (bcma) targeted therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The b-cell maturation antigen (bcma) targeted therapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Antibody Drug Conjugates; Chimeric Antigen Receptor T (CAR-T)-Cell Therapy; Bispecific Antibodies
• 2) By Indication Type: Acute Lymphoblastic Leukemia; Multiple Myeloma
• 3) By End User: Hospitals; Specialty Clinics; Home Care Settings
• Subsegments:
• 1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates); Linker-Payload Technology-Based BCMA ADCs
• 2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous); Allogeneic BCMA CAR-T Cells
• 3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies; BCMA x CD28 Bispecific Antibodies
• Companies Mentioned: Bristol Myers Squibb Company; Novartis; GlaxoSmithKline (GSK); Takeda Pharmaceutical Company Limited; Amgen Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Characteristics

3. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Trends And Strategies

4. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Growth Analysis And Strategic Analysis Framework

• 5.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate Analysis
• 5.4. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Total Addressable Market (TAM)

6. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Segmentation

• 6.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibody Drug Conjugates
• Chimeric Antigen Receptor T (CAR-T)-Cell Therapy
• Bispecific Antibodies
• 6.2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Lymphoblastic Leukemia
• Multiple Myeloma
• 6.3. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Home Care Settings
• 6.4. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Antibody Drug Conjugates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• BCMA-Targeted ADCs (Antibody-Drug Conjugates)
• Linker-Payload Technology-Based BCMA ADCs
• 6.5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• BCMA CAR-T Cells (Autologous)
• Allogeneic BCMA CAR-T Cells
• 6.6. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• BCMA x CD3 Bispecific Antibodies
• BCMA x CD28 Bispecific Antibodies

7. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Regional And Country Analysis

• 7.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 8.1. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 9.1. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
• 9.2. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 10.1. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 11.1. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
• 11.2. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 12.1. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 13.1. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 14.1. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
• 14.2. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 15.1. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
• 15.2. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 16.1. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 17.1. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 18.1. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 19.1. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 20.1. Spain B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 21.1. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
• 21.2. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 22.1. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 23.1. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
• 23.2. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 24.1. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
• 24.2. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 25.1. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
• 25.2. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 26.1. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
• 26.2. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 27.1. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 28.1. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
• 28.2. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

• 29.1. Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
• 29.2. Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Competitive Landscape And Company Profiles

• 30.1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Competitive Landscape
• 30.2. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Company Profiles
  • 30.2.1. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline (GSK) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amgen Inc Overview, Products and Services, Strategy and Financial Analysis

31. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Other Major And Innovative Companies

• 31.1. Regeneron Pharmaceuticals
• 31.2. Beigene
• 31.3. Arcellx Inc
• 31.4. Poseida Therapeutics
• 31.5. Legend Biotech Corporation
• 31.6. Cartesian Therapeutics
• 31.7. Juno Therapeutics
• 31.8. Sutro Biopharma Inc
• 31.9. CARsgen Therapeutics
• 31.10. Precision BioSciences
• 31.11. Eureka Therapeutics Inc
• 31.12. Cellectis
• 31.13. Teneobio Inc.
• 31.14. Janssen Pharmaceuticals Companies
• 31.15. Allogene Therapeutics

32. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

34. Recent Developments In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

35. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market High Potential Countries, Segments and Strategies

• 35.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market In 2029 - Countries Offering Most New Opportunities
• 35.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market In 2029 - Segments Offering Most New Opportunities
• 35.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer